Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer | Zendy

Maha Hussain | Zendy; Karim Fizazi | Zendy; Fred Saad | Zendy; Per Rathenborg | Zendy; Neal D. Shore | Zendy; Ubirajara Ferreira | Zendy; Petro Ivashchenko | Zendy; Eren Demirhan | Zendy; Katharina Modelska | Zendy; De Phung | Zendy; Andrew Krivoshik | Zendy; Cora N. Sternberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Author(s) -

Maha Hussain,

Karim Fizazi,

Fred Saad,

Per Rathenborg,

Neal D. Shore,

Ubirajara Ferreira,

Petro Ivashchenko,

Eren Demirhan,

Katharina Modelska,

De Phung,

Andrew Krivoshik,

Cora N. Sternberg

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1800536

Subject(s) - enzalutamide , prostate cancer , medicine , oncology , castration , cancer , urology , androgen receptor , hormone

Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research